===============================================================================
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): January 15, 2006
ROCKWELL MEDICAL TECHNOLOGIES, INC.
(Exact name of registrant as specified in its charter)
Michigan 000-230-661 38-3317208
---------------------------- ------------ ----------
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No.)
30142 Wixom Road, Michigan 48334
--------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (248) 960-9009
Not applicable
------------------------------------------
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17CFR
240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act (17 CFR 240.13e-4(c))
===============================================================================
ITEM 1.01 ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT.
On January 15, 2006, Rockwell Medical Technologies, Inc. ("Rockwell")
entered into an amending agreement with Charak LLC ("Charak") and Dr. Ajay Gupta
(the "Amendment"), which amended the existing licensing agreement among the
parties dated January 7, 2002. Pursuant to the Amendment, Charak granted
Rockwell an exclusive license to make, manufacture and sell a water-soluble
vitamin and carnitine mixture for dialysis patients which is covered by a U.S.
patent. The patent covers the method for preventing and correcting vitamin
deficiency in both hemodialysis and peritoneal dialysis patients with renal
failure. Prior to marketing the product, Rockwell will have to obtain US Food &
Drug Administration (FDA) approval.
There is no material relationship between Rockwell and any of the
parties to the Amendment other than as described above.
ITEM 7.01 REGULATION FD DISCLOSURE.
The information described above under "Item 1.01 Entry into a Material
Definitive Agreement" is hereby incorporated herein by reference.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
ROCKWELL MEDICAL TECHNOLOGIES, INC.
Date: January 19, 2006 By: /S/ Thomas E. Klema
---------------------------------
Thomas E. Klema
Its: Chief Financial Officer
3